Addendum: Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report
Oncotarget. 2023 May 10:14:438.
doi: 10.18632/oncotarget.28428.
1 The Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
2 Department of Pathology and Laboratory Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
3 Department of Neurosurgery, Temple University School of Medicine, Philadelphia, PA 19140, USA.